ADMA Biologics Inc vs SpaceX — how do they compare? ADMA Biologics Inc trades at $9.94 (market cap $2.22B), while SpaceX trades at $142.3 (market cap $1.76T). The key difference: SpaceX is far larger — about 792.8× ADMA Biologics Inc's market cap, and SpaceX is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | SPCX | |
|---|---|---|
Market Cap | $2.22B | $1.76T |
Sector | Health | Technology |
52-Week High | $20.38 | $202.09 |
52-Week Low | $7.60 | $108.27 |
Enterprise Value | $2.29B | $1.70T |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.
Read more on SPCX →